TOPAZ PHARMACEUTICALS INC. – Trademark Portfolio
Entity Type: 03
TOPAZ PHARMACEUTICALS INC. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include SKLICE. The owner is based in HORSHAM, PA.
100 WITMER ROAD, SUITE 280
HORSHAM, PA 19044
Showing of trademarks Trademarks
Trademark Classifications
TOPAZ PHARMACEUTICALS INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does TOPAZ PHARMACEUTICALS INC. have?
TOPAZ PHARMACEUTICALS INC. has 10 U.S. trademarks filed with the USPTO. Of these, 1 registered, 7 abandoned, 2 cancelled.
What trademark classes does TOPAZ PHARMACEUTICALS INC. file in?
TOPAZ PHARMACEUTICALS INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are TOPAZ PHARMACEUTICALS INC.'s most well-known trademarks?
TOPAZ PHARMACEUTICALS INC.'s registered trademark portfolio includes well-known marks such as SKLICE. These are among 1 currently registered trademark in the portfolio.
What is TOPAZ PHARMACEUTICALS INC.'s trademark registration success rate?
TOPAZ PHARMACEUTICALS INC. has a 10% trademark registration rate, with 1 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.